Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions
Open Access
- 1 October 2019
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 48, 191-202
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Ligue Contre le Cancer (LNCC 2017)
- Institut National Du Cancer (PRT-K-15-039)
This publication has 40 references indexed in Scilit:
- Restoration of natural killer cell cytotoxicity by VEGFR-3 inhibition in myelogenous leukemiaCancer Letters, 2014
- VISTA Is an Immune Checkpoint Molecule for Human T CellsCancer Research, 2014
- Mésothéliome : les dispositifs en place en France « le réseau mésothéliome » 1998–2013Annales de Pathologie, 2014
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Use of alternative time scales in Cox proportional hazard models: implications for time‐varying environmental exposuresStatistics in Medicine, 2012
- Epithelial–mesenchymal transition in malignant mesotheliomaLaboratory Investigation, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Prognostic significance of epithelial–mesenchymal transition in malignant pleural mesothelioma☆☆☆European Journal of Cardio-Thoracic Surgery, 2010
- Immunohistochemical expression and distribution of VEGFR-3 in malignant mesotheliomaDiagnostic Cytopathology, 2007
- Estimation of time‐dependent area under the ROC curve for long‐term risk predictionStatistics in Medicine, 2005